论文信息 - Aprepitant improves refractory pruritus in primary cutaneous T‐cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas

Aprepitant improves refractory pruritus in primary cutaneous T‐cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas

Aprepitant has shown a promising anti-itch activity in several cases of cutaneous T-cell lymphomas (CTCLs)1-8. We sought to determine its antipruritic efficacy in a large multicenter series of CTCLs patients with refractory pruritus and, secondarily, to define possible clinical predictors of response.A retrospective, analytical review of the Spanish Working Group on Cutaneous Lymphoma database was designed to collect patients with CTCLs and refractory pruritus, treated with aprepitant from 2009 to 2013. This article is protected by copyright. All rights reserved.

[1] T. Kupper,et al. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature , 2017, BMC Cancer.

[2] A. L. Querejazu,et al. Papel del aprepitant en el manejo del prurito en un paciente con linfoma cutáneo de células T , 2014 .

[3] E. Olsen,et al. Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. , 2012, Journal of the American Academy of Dermatology.

[4] J. Utikal,et al. Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T‐cell lymphoma , 2011, The British journal of dermatology.

[5] L. Dubertret,et al. Aprepitant as an antipruritic agent? , 2009, The New England journal of medicine.

[6] J. Márquez Enríquez,et al. Treatment of pruritus in early‐stage hypopigmented mycosis fungoides with aprepitant , 2014, Dermatologic therapy.

[7] A. López-Pestaña,et al. Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma. , 2014, Actas dermo-sifiliograficas.

[8] A. Santos Ibáñez,et al. [Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma]. , 2014, Farmacia Hospitalaria.

[9] T. Torres,et al. Aprepitant: Evidence of its effectiveness in patients with refractory pruritus continues. , 2012, Journal of the American Academy of Dermatology.